Barclays Issues Positive Forecast for Cigna Group (NYSE:CI) Stock Price

Cigna Group (NYSE:CI) had its target price increased by Barclays from $304.00 to $310.00 in a report issued on Friday morning,Benzinga reports. They currently have an equal weight rating on the health services provider’s stock.

Several other equities research analysts also recently weighed in on CI. Wolfe Research reaffirmed an “outperform” rating and issued a $315.00 price target on shares of Cigna Group in a research note on Tuesday, June 16th. UBS Group increased their price objective on shares of Cigna Group from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Morgan Stanley raised their target price on Cigna Group from $355.00 to $361.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Jefferies Financial Group decreased their target price on Cigna Group from $333.00 to $330.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Finally, Royal Bank Of Canada upped their price target on Cigna Group from $333.00 to $337.00 and gave the stock an “outperform” rating in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $341.60.

Cigna Group Stock Performance

Shares of CI stock opened at $279.27 on Friday. The firm has a 50 day moving average of $286.62 and a 200-day moving average of $281.10. The company has a market cap of $73.88 billion, a price-to-earnings ratio of 11.55, a price-to-earnings-growth ratio of 1.11 and a beta of 0.29. The company has a quick ratio of 0.73, a current ratio of 0.76 and a debt-to-equity ratio of 0.68. Cigna Group has a 52 week low of $239.51 and a 52 week high of $315.47.

Cigna Group (NYSE:CI) last released its earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.60 by $0.18. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. The company had revenue of $70.04 billion for the quarter, compared to the consensus estimate of $70.14 billion. During the same quarter in the previous year, the company earned $7.20 EPS. Cigna Group’s quarterly revenue was up 6.7% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.450- EPS. On average, equities analysts forecast that Cigna Group will post 30.4 earnings per share for the current year.

Cigna Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a dividend of $1.56 per share. The ex-dividend date is Tuesday, September 8th. This represents a $6.24 annualized dividend and a yield of 2.2%. Cigna Group’s dividend payout ratio is presently 26.45%.

Insiders Place Their Bets

In related news, CAO Jamie G. Kates sold 899 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $298.61, for a total value of $268,450.39. Following the sale, the chief accounting officer owned 2,368 shares in the company, valued at $707,108.48. This represents a 27.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO David Cordani sold 201,878 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total transaction of $59,113,915.96. Following the completion of the sale, the chief executive officer owned 34,337 shares in the company, valued at $10,054,560.34. This represents a 85.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cigna Group

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Cigna Group by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 26,173,577 shares of the health services provider’s stock worth $7,203,754,000 after purchasing an additional 414,834 shares during the last quarter. State Street Corp boosted its position in shares of Cigna Group by 1.8% during the fourth quarter. State Street Corp now owns 12,339,250 shares of the health services provider’s stock valued at $3,396,132,000 after buying an additional 224,122 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Cigna Group by 8.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 11,805,083 shares of the health services provider’s stock valued at $3,249,113,000 after buying an additional 903,334 shares during the last quarter. Dodge & Cox grew its holdings in Cigna Group by 19.7% during the fourth quarter. Dodge & Cox now owns 11,138,614 shares of the health services provider’s stock worth $3,065,681,000 after buying an additional 1,833,389 shares in the last quarter. Finally, GQG Partners LLC raised its position in Cigna Group by 14.3% in the 4th quarter. GQG Partners LLC now owns 7,763,295 shares of the health services provider’s stock valued at $2,136,699,000 after buying an additional 972,302 shares during the last quarter. Institutional investors and hedge funds own 86.99% of the company’s stock.

Key Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna reported adjusted second-quarter earnings of $7.78 per share, above the roughly $7.60 consensus estimate, while revenue rose 7% year over year to approximately $71.7 billion. Cigna Healthcare revenue increased 9%, and Evernorth Health Services revenue grew 6%. Cigna Q2 results and outlook
• Positive Sentiment: Management raised its 2026 adjusted earnings outlook to at least $30.45 per share, implying approximately 10% earnings growth, supported by strength across the healthcare and pharmacy-benefit businesses. Cigna raises annual profit forecast
• Positive Sentiment: Analyst sentiment remains constructive: Barclays raised its price target from $304 to $310 while retaining an “equal weight” rating. A separate analysis highlighted CI’s discounted valuation, ongoing share repurchases, strong cash generation, and $1.56-per-share dividend. Cigna valuation analysis
• Neutral Sentiment: The earnings beat was accompanied by revenue that was slightly below some analyst estimates, and Barclays’ “equal weight” stance suggests the improved outlook may already be partly reflected in the stock.
• Negative Sentiment: Cigna expects lower growth in prescriptions for popular GLP-1 drugs. Because these treatments are a significant growth area for pharmacy services, slower utilization could temper future revenue and profit expansion. Cigna GLP-1 prescription outlook
• Negative Sentiment: Elevated medical costs and higher pharmacy expenses remain industrywide risks. Those pressures may explain why investors initially treated the guidance increase cautiously despite Cigna’s higher profit and broad-based operating growth.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.